Five years follow-up study and failures analysis of Botulinum toxin repeated injections to treat neurogenic detrusor overactivity

Progres en Urologie

Volumn 22, Issue 17, 2012, Pages 1064-1070

  Gaillet, S ^a,b   Bardot, P ^e   Bernuz, B ^a,b,d   Boissier, R ^a,b   Lenne Aurier, K ^b   Thiry Escudier, I ^a,b,d   Tournebise, H ^a,b,c   Lechevallier, E ^a,b   Karsenty, G ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

^c Hôpital Renée Sabran   (France)

^d Hôpital Leon Berard   (France)

^e Institut Pomponiana Olbia   (France)

Author keywords

Botulinum toxin; Neurogenic bladder; Overactive bladder; Treatment failure; Urinary incontinence

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTICLE; FEMALE; FOLLOW UP; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MALE; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PROSPECTIVE STUDY; RETREATMENT; TIME; TREATMENT FAILURE;

ADMINISTRATION, INTRAVESICAL; ADULT; BOTULINUM TOXINS, TYPE A; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROSPECTIVE STUDIES; RETREATMENT; TIME FACTORS; TREATMENT FAILURE; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE;

EID: 84870236236     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2012.10.006     Document Type: Article

References (30)

1. Karsenty G., et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 2008, 53(2):275-287.
2. Perrouin-Verbe B., et al. Criteria and best clinical practice guidelines for first intradetrusor injection of botulinum toxin type A to treat neurogenic detrusor overactivity. Prog Urol 2009, 19(6):372-382.
3. Stohrer M., et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009, 56(1):81-88.
4. Wyndaele J.J., et al. Neurologic urinary incontinence. Neurourol Urodyn 2010, 29(1):159-164.
5. Apostolidis A., et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 2009, 55(1):100-119.
6. Costa P., et al. Quality of life in spinal cord injury patients with urinary difficulties. Development and validation of qualiveen. Eur Urol 2001, 39(1):107-113.
7. Bonniaud V., et al. Symptom and quality of life assessment in urinary disorders. Ann Readapt Med Phys 2005, 48(6):392-403.
8. Patel A.K., Patterson J.M., Chapple C.R. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: A critical analysis of results. Eur Urol 2006, 50(4):684-709. [discussion 709-10].
9. Khan S., et al. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol 2011, 185(4):1344-1349.
10. Reitz A., et al. Do repeat intradetrusor botulinum toxin type a injections yield valuable results?. Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol 2007, 52(6):1729-1735.
11. Grosse J., Kramer G., Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005, 47(5):653-659.
12. Chenet A., et al. Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity. Ann Readapt Med Phys 2007, 50(8):651-660.
13. Del Popolo G., et al. Neurogenic detrusor overactivity treated with English botulinum toxin A: 8-year experience of one single centre. Eur Urol 2008, 53(5):1013-1020.
14. Klaphajone J., Kitisomprayoonkul W., Sriplakit S. Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low compliance bladder in patients with spinal cord lesions. Arch Phys Med Rehabil 2005, 86(11):2114-2148.
15. Horst M., et al. Repeated Botulinum-A toxin injection in the treatment of neuropathic bladder dysfunction and poor bladder compliance in children with myelomeningocele. Neurourol Urodyn 2011, 30(8):1546-1549.
16. Karsenty G., et al. Pharmacological treatment of neurogenic detrusor hyperactivity: intradetrusor botulinum toxin A injections. Prog Urol 2007, 17(3):568-575.
17. Anderson T.J., et al. Botulinum toxin treatment of spasmodic torticollis. J Royal Soc Med 1992, 85(9):524-529.
18. Greene P., Fahn S., Diamond B. development of resistance to botulinum toxin type-a in patients with torticollis. Mov Disord 1994, 9(2):213-217.
19. Goschel H., et al. Botulinum a toxin therapy: Neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp Neurol 1997, 147(1):96-102.
20. Rollnik J.D., et al. Neutralizing botulinum toxin type a antibodies: clinical observations in patients with cervical dystonia. Neur Clin Neurophysiol 2001, 2001(3):2-4.
21. ®) across multiple indications. Mov Disord 2010, 25(13):2211-2218.
22. Holds J.B., et al. Motor-nerve sprouting in human orbicularis muscle after botulinum-a injection. Invest Ophthalmol Vis Sci 1990, 31(5):964-967.
23. Schulte-Baukloh H., et al. Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure. Int J Urol 2008, 15(5):407-415.
24. ®) detrusor injection. Urol Int 2011, 87(4):434-438.
25. Kajbafzadeh A.-M., et al. Antibody formation following botulinum toxin type A (Dysport) injection in children with intractable bladder hyper-reflexia. Urology 2010, 76(1):233-237.
26. Hegele A., et al. Antibodies after botulinum toxin A injection into musculus detrusor vesicae: incidence and clinical relevance. Urol Int 2011, 87(4):439-444.
27. Apostolidis A., et al. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 2008, 53(6):1245-1253.
28. Comperat E., et al. Histologic features in the urinary bladder wall affected from neurogenic overactivity - a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 2006, 50(5):1058-1064.
29. Haferkamp A., et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol 2004, 46(6):784-791.
30. Mohee A., et al. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int 2012, [Article first published online: 6 Jun 2012].